Publications
November 11, 2022
Abstract: PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion
Ophir, E, et al, SITC 2022
November 11, 2022
Poster: PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion
Ophir, E, et al, SITC 2022
November 11, 2022
Presentation: PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion
Ophir, E, et al, SITC 2022
November 10, 2022
Abstract: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases.
Overman, M, J et al, SITC 2022
November 10, 2022
Poster: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases.
Overman, M, J et al, SITC 2022
November 10, 2022
Presentation: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases.
Overman, M, J et al, SITC 2022
November 7, 2022
Gene model correction for PVRIG in single cell and bulk sequencing data enables accurate detection and study of its functional relevance
Sergey Nemzer, Niv Sabath, Assaf Wool, Zoya Alteber, Hirofumi Ando, Amanda Nickles-Fader, Tian-Li Wang, Ie-Ming Shih, Drew M. Pardoll, Sudipto Ganguly, Yaron Turpaz, Zurit Levine, Roy Z Granit
September 30, 2022
Potential of PVRIG and TIGIT blockade in addressing immunotherapy resistance
Eran Ophir, Immuno UK, London, UK, 30 September 2022
June 28, 2022
PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials
Pierre Ferré, AIS 2022 Montpellier, France, 28 June 2022
